Evaluate IBRX stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in IBRX? | Glauxie AI

Q: What are the risks of investing in IBRX?

ImmunityBio, Inc. (IBRX) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Richard Gerald Adcock. ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including... Employees: 79,320.

Q: How much debt does IBRX have?

Review IBRX total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is IBRX a good long-term investment?

Evaluate IBRX as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in IBRX?

🦉

ImmunityBio, Inc. (IBRX)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEORichard Gerald Adcock

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer...

Key Executives

Name	Title
Barry J. Simon	Chief Corporation Affairs Officer & Director
David C. Sachs	Chief Financial Officer
Emily Arison	Senior Vice President of Human Resources
Enrique Diloné	Chief Technology Officer
Hans Georg Klingemann	Chief Science Officer of Cellular
Leonard S. Sender	Chief Medical Officer of Liquid Tumors & Cell Therapy

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

IBRX Profile Financials

Is IBRX stock safe? How much debt does IBRX have? Is IBRX a good long-term investment?